B/BE/01/V6
| Company/Institution | Pharmacia Animal health |
| Parental organism | Salmonella enterica serotype Dublin and Salmonella enterica serotype Typhimurium |
| Transgene(s) | genetic modification of Salmonella enterica by deletion of 2 genes (ssaC and ssaT) |
| Treated organism | calves |
| Title of the project | Evaluation of efficacy of Salmonella Dublin-Typhimurium vaccine, double gene deleted avirulent live culture in calves. |
| Treatment indication | vaccination against Salmonella Dublin and Salmonella Typhimurium |
| Administration route(s) | subcutaneous |
| Total number of subjects foreseen | 100 |
| Foreseen duration of release | 12 months |
| Effective year(s) of release | - |
| Current status | No authorization - trial never started |
| Locations | 2 farms located in Flanders were to be selected |
| Number of sites | 2 |
| Monitoring | |
| Type of procedure | Classical procedure - Art. 9§1 of Royal Decree of 18 December 1998 |
| Notes | |
| Other |
Information for the public
-
B/BE/01/V6 - Summary Notification Information Format (SNIF)
Public information presented according to the provisions of Directive 2001/18/EC
- B/BE/01/V6 - Fiche d'information destinée au public (préparée par le notifiant)
- B/BE/01/V6 – Informatie fiche bestemd voor het publiek (voorbereid door de kennisgever)
Information related to the decision procedure
-
B/BE/01/V6 - Advies van de a.i. Adviesraad voor Bioveiligheid / Avis du Conseil Consultatif de Biosécurité a.i.
4 February 2002: The Biosafety Advisory Council a.i. issues a negative advice for this trial (the advice is written in French and Dutch)
